Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia (NCT04608032) | Clinical Trial Compass
UnknownNot Applicable
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
France70 participantsStarted 2020-09-08
Plain-language summary
This study evaluates the effect of a cognitive remediation program on neurocognitive, social cognitive and metacognitive functions designed for patients living with a schizophrenia spectrum disorder.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Schizophrenia Disorder diagnosis, according to Diagnostic and Statistical Manual of mental disorders - Fifth edition (DSM-V) - Patient stabilized in terms of positive and negative symptomatology (absence or presence of weak positive and negative symptoms)
* Positive and Negative stable symptoms (no or few positive and negative symptoms)
* Stable and effective minimum dose of medication (antipsychotic) for the last three months
* Cognitive complaint expressed by the patient
* Informed consent form read, initialed and signed
* Understanding of spoken and read French
* Patient registered on the social welfare system
Exclusion Criteria:
* Other diagnosis at the forefront than Schizophrenia of the DSM-V
* Medical history neurological disorder resulting in hospitalization
* Acute episode in the last three month
* Somatic disorders resulting in cognitive impairment
* Engagement in a research protocol either currently or over the last month
* Neuropsychological assessment evaluation during the last six month
* Patients under the protection of a conservator (simple or reinforced)
* Individuals in vulnerable circumstances